

해외 바이오의약품 임상 현황 (2020.11.02~2020.11.08)

한국바이오의약품협회, 2020.11.10
출처: ClinicalTrials.gov

○ 미국 25건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04548583	Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis	Crohn Colitis	Drug: remesetemcel-LJOther: Placebo	The Cleveland Clinic Mesoblast, Inc.	Phase 1 Phase 2
NCT04616586	SILTuximab in Viral ARds (SILVAR) Study	Acute Respiratory Distress Syndrome Lung Diseases Pneumonia Respiratory Tract Infections Respiratory Tract Disease	Drug: Siltuximab Other: Normal Saline	EusaPharma (UK) Limited Syneos Health	Phase 3
NCT04612023	An Amniotic Membrane Injection Comparing Two Doses (1 mL and 2 mL Injection) and a Placebo (Sterile Saline) in the Treatment of Osteoarthritis of the Knee	Osteoarthritis, Knee	Other: Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)	Illinois Center for Orthopaedic Research and Education	Phase 2
NCT04611789	A Study of LY3832479 (LY-CoV016) in Healthy Participants 1	Healthy	Drug: LY3832479 Drug: Placebo	Eli Lilly and Company Shanghai Junshi Bioscience Co., Ltd.	Phase 1
NCT04578535	A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants	Healthy Volunteers	Drug: HYQVIA	Baxalta now part of Shire Baxalta Innovations GmbH, now part of Shire Takeda	Phase 1
NCT04560972	LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer	Extensive Stage Lung Small Cell Carcinoma	Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Protein Phosphatase 2A Inhibitor LB-100	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04477343	A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma Pancreatic Cancer	Drug: SX-682 Drug: Nivolumab Injectable Product	University of Rochester Syntrix Biosystems, Inc. Bristol-Myers Squibb	Phase 1
NCT04442581	Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer	Advanced Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma	Drug: Cabozantinib S-malate Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI)	Phase 2
NCT04401410	Anti-SARS Cov-2 T Cell Infusions for COVID 19	SARS-CoV 2 Viral Infection COVID 19	Biological: Dose Finding Phase (MTD) Biological: Partially HLA-matched SARS-CoV2s Other: Routine care (no SARS-CoV2s)	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital System AlloVir	Phase 1
NCT04387227	Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma	Drug: Carboplatin Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2
NCT04384692	Ruxolitinib for the Treatment of Graft Versus Host Disease Following Stem Cell Transplant in Patients With Primary and Secondary Myelofibrosis	Primary Myelofibrosis Secondary Myelofibrosis	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Busulfan Drug: Cyclophosphamide Drug: Fludarabine Drug: Melphalan Drug: Methotrexate Drug: Mycophenolate Mofetil Drug: Ruxolitinib Drug: Tacrolimus Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04383743	Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer	Stage II Bladder Cancer AJCC v8 Stage IIIA Bladder Cancer AJCC v8	Drug: Cisplatin Drug: Doxorubicin Drug: Methotrexate Biological: Pegfilgrastim Biological: Pembrolizumab Procedure: Radical Cystectomy Drug: Vinblastine Sulfate	University of Washington National Cancer Institute (NCI) Merck Sharp & Dohme Corp.	Phase 2
NCT04375631	CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia	Recurrent Acute Myeloid Leukemia Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Chronic Myelomonocytic Leukemia Refractory Mixed Phenotype Acute Leukemia Refractory Myelodysplastic Syndrome Refractory Acute Leukemia of Ambiguous Lineage Refractory Acute Undifferentiated Leukemia	Drug: Cladribine Drug: Cyclophosphamide Drug: Cyclosporine Drug: Cytarabine Biological: Filgrastim Procedure: Hematopoietic Cell Transplantation Drug: Mitoxantrone Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 1
NCT04372927	ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy	Locally Advanced Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8	Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2
NCT04370301	Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	Primary Myelofibrosis Secondary Myelofibrosis	Drug: Cyclophosphamide Drug: JAK Inhibitor Drug: Fludarabine Biological: Recombinant Granulocyte Colony-Stimulating Factor Drug: Melphalan Drug: Mycophenolate Mofetil Procedure: Peripheral Blood Stem Cell Transplantation Drug: Tacrolimus Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04359784	Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	B-Cell Non-Hodgkin Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleucel	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Sobi	Phase 2
NCT04336943	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load	Biochemically Recurrent Prostate Carcinoma Prostate Adenocarcinoma	Biological: Durvalumab Drug: Olaparib Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2

해외 바이오의약품 임상 현황 (2020.11.02~2020.11.08)

한국바이오의약품협회, 2020.11.10
출처: ClinicalTrials.gov

NCT04329065	Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer	Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8	Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Drug: Paclitaxel Biological: Trastuzumab Biological: Pertuzumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2
NCT04174560	Phase I Norovirus Challenge Model	Gastroenteritis Norovirus	Biological: Norovirus GII.4 Challenge Pool	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
NCT04607733	A Study of Mirikizumab in Healthy Participants	Healthy	Drug: Mirikizumab Prefilled Syringe Drug: Mirikizumab Autoinjector	Eli Lilly and Company	Phase 1
NCT04165083	Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYNOTE-01B)	Carcinoma, Non-Small-Cell Lung	Biological: Pembrolizumab Biological: MK-4830	Merck Sharp & Dohme Corp.	Phase 2
NCT04614948	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults	Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol	Biological: Ad26.COV2.S Other: Placebo	Janssen Vaccines & Prevention B.V.	Phase 3
NCT04605991	A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)	Type 2 Diabetes	Drug: LY900014 Drug: Insulin Glargine	Eli Lilly and Company	Phase 3
NCT04612790	A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.	Bullous Pemphigoid	Biological: Benralizumab Biological: Placebo	AstraZeneca	Phase 3
NCT04596631	A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: Oral semaglutide Drug: Placebo (semaglutide)	Novo Nordisk A/S	Phase 3

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04614948	No Results Available	Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol	Biological: Ad26.COV2.S Other: Placebo	Janssen Vaccines & Prevention B.V.	Phase 3

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04547062	Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)	Acute Myeloid Leukemia (AML)	Drug: Tocilizumab	Nantes University Hospital	Phase 1
NCT04614948	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults	Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol	Biological: Ad26.COV2.S Other: Placebo	Janssen Vaccines & Prevention B.V.	Phase 3

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04617691	A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vial Product in Healthy Participants	Healthy	Drug: Guselkumab	Janssen Research & Development, LLC	Phase 1
NCT04612790	A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.	Bullous Pemphigoid	Biological: Benralizumab Biological: Placebo	AstraZeneca	Phase 3
NCT04614948	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults	Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol	Biological: Ad26.COV2.S Other: Placebo	Janssen Vaccines & Prevention B.V.	Phase 3

○ 중국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04235959	A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus	Diabetes Mellitus, Type 2	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 1